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Abstract
Background: Signaling through vascular endothelial growth factor C (VEGF–C) and VEGF receptor 3 (VEGFR-3) plays
a central role in lymphangiogenesis and the metastasis of several cancers via the lymphatics. Recently, the Slit2/
Robo4 pathway has been recognized as a modulator of vascular permeability and integrity. Signaling via the Robo
receptor inhibits VEGF-mediated effects; however, its effects on lymphatic endothelial cell function have not been
well characterized.
Results: We found that pretreatment with Slit2N, an active fragment of Slit2, inhibited VEGF-C-mediated lung-derived
lymphatic endothelial cell (L-LEC) proliferation, migration, and in vitro tube formation. Slit2N induced the internalization of
VEGFR-3, which blocked its activation, and inhibited the activation of the PI3K/Akt pathway by VEGF-C in L-LECs. Moreover,
we found that inhibition of VEGF-C-induced effects by Slit2N was Robo4-dependent.
Conclusion: These results indicate that Slit2N/Robo4 modulates several key cellular functions, which contribute to
lymphangiogenesis, and identify this ligand-receptor pair as a potential therapeutic target to inhibit lymphatic metastasis
of VEGF-C-overexpressing cancers and manage lymphatic dysfunctions characterized by VEGF-C/VEGFR-3 activation.
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Lay abstract
Cellular signaling initiated by the binding of vascular endothelial growth factor C (VEGF-C) to the receptor, VEGFR-3,
is central to the growth of lymphatic channels, their constituent endothelial cells, and the spread of several types of
cancer via the lymphatic system. Signaling through the ligand-receptor pair, Slit2/Robo4, modulates the permeability and
integrity of vascular endothelium, the cells that line blood vessels. The Slit2/Robo pathway inhibits cellular effects induced
by VEGF; however, its effects on lymphatic channels and lymphatic endothelium have not been fully studied.
We found that pretreating lung-derived lymphatic endothelial cells (L-LECs) with Slit2N, an active fragment of the protein
Slit2, inhibited VEGF-C-induced functions critical for the formation of the lymphatics, i.e. lymphangiogenesis. Specifically,
it blocked the growth and migration of L-LECs, and the formation of tube-like structures on a gelatinous matrix. Slit2N
induced the internalization VEGR-3, which blocked its activation, and inhibited signaling through PI3K/Akt, a pathway that
modulates diverse cellular processes, including cell growth and cancer progression. In addition, we found that inhibition
of VEGF-C-induced effects by Slit2N required sufficient levels of Robo4, indicating that Robo4 is the receptor to which
Slit2N binds to inhibit the aforementioned effects.
These results indicate that Slit2N/Robo4 modulates key cellular functions that contribute to lymphangiogenesis, and
identify this ligand-receptor pair as a potential drug target to inhibit cancer metastasis via the lymphatic system and to
treat other lymphatic pathologies characterized by abnormal VEGF-C/VEGFR-3 signaling.
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The lymphatic system plays critical roles in the mainten-
ance of fluid homeostasis, immune response, and tumor
metastasis [1]. VEGF-C/VEGFR-3 signaling is a key modu-
lator of this system [2-4]. Many cancers express VEGF-C
[5-16]. Clinical studies demonstrate that VEGF-C levels
correlate with lymph node metastasis and poor prognosis
[8,14,17-25], and multiple tumor types preferentially me-
tastasize through lymphatic vessels versus blood vascular
dissemination or direct seeding [26,27]. Tumor-induced
lymphangiogenesis plays an active role in the induction of
metastasis to the lymph nodes in these cancers [28].
Given the role of the VEGF-C/VEGFR-3 signaling in
tumor lymphangiogenesis and metastasis, inhibiting this
pathway with soluble VEGFR-3, neutralizing antibodies
to VEGFR-3 or VEGF-C, or suppressing VEGF-C expres-
sion with siRNAs can reduce lymph node and organ me-
tastasis in rodent models [29-32]. Moreover, VEGF-C/
VEGFR-3 signaling does not appear to be required for the
maintenance of lymphatic vessels beyond development,
since prolonged inhibition of VEGFR-3 signaling in ani-
mals impedes lymph node metastasis with no apparent
effects on preexisting, mature, lymphatic vessels in adja-
cent tissue [31,33-35]. These data suggest that VEGF-C/
VEGFR-3 signaling in lymphatic endothelium may be an
attractive target to restrict cancer metastasis via the lym-
phatics [36].
Tumor cells and tumor-associated macrophages ap-
pear to be the primary sources of lymphangiogenic fac-
tors including VEGF-C [37-39]. Its receptor, VEGFR-3, is
predominantly expressed by lymphatic endothelial cells
[40]. Of note, in mouse models of melanoma and breast
cancer, lymphangiogenesis in the draining lymph nodes
precedes the arrival of any tumor cells, and is enhanced
further after metastasis to the nodes [7,41]. These data
suggest that tumor-secreted VEGF-C may act in a para-
crine fashion by draining to the sentinel lymph nodes
and modulating the lymphatic microenvironment both
before metastasis and after tumor cells have migrated to
the lymph nodes [41]. It is this model of the effects of
exogenous VEGF-C on LECs that we recapitulate here.
The Slit and Robo proteins were first characterized as
modulators of axon guidance and repulsion in central ner-
vous system development [42]. The Slit proteins (Slits 1–3)
are a group of glycoproteins containing various functional
domains including a leucine-rich repeat (LRR) region,
which is important for binding to their cognate Robo re-
ceptors [43]. Among the four Robo proteins that have been
identified in mammals [44-47], the structure of Robo4 is
unique. In contrast to the other Robo proteins, its extracel-
lular region contains fewer Ig-like domains and fewer fibro-
nectin (Fn) type III repeats; and its intracellular domain
contains only two of five cytoplasmic conserved (CC) mo-
tifs [48]. Its nearly exclusive expression on endothelial cells
also distinguishes Robo4 from the other Robo proteins [48].
In vivo, Slit2 is proteolytically cleaved into an N-terminal,
140 kDa fragment (Slit2N), and a C-terminal, 55–60 kDa
fragment (Slit2C) [42,49]. Importantly, this cleavage
was also observed in kidney cells manipulated to over-
express recombinant Slit2, demonstrating that the
proteolytic processing of Slit2 is recapitulated in vitro
[42]. Functional studies have shown that Slit2N, but
not Slit2C, can associate witht h eR o b o sa n dm o d u l a t es i g -
naling downstream of these receptors [49-51]; therefore, we
employed recombinant Slit2N in this study.
In addition to their roles in nervous system development,
Slit and Robo proteins modulate vascular endothelial cell
function. Slit2/Robo4 inhibits in vitro transwell migration
of human microvascular endothelial cells (HMVEC) and
human umbilical vein endothelial cells (HUVEC); they pro-
mote vascular stability and inhibit hyperpermeability in a
mouse model of retinal permeability [52]. Accumulating
evidence indicates that Slit2/Robo4 modulates angiogenesis
by inhibiting VEGF signaling in vascular endothelial cells
[53,54]; in contrast, several studies have reported that Slit2/
Robo activation can stimulate vascular endothelial cell
proliferation and migration, and increase tumor metas-
tasis [55-57]. Remarkably, little is known about the ef-
fects of Slit/Robo on the lymphatic system; therefore,
we sought to evaluate signaling via Slit2N/Robo4 on
VEGF-C-induced functions in L-LECs. We observed
that Slit2N and Robo4 inhibited VEGF-C-induced
lymphatic endothelial cell proliferation, migration, and
tube formation by blocking the activation of VEGFR-3
and signaling through Phosphatidylinositide 3-kinase
(PI3K) and Protein kinase B (Akt). In addition, Slit2N/
Robo4 enhanced the internalization of VEGFR-3. As
novel mediators of lymphangiogenesis, Slit2 and Robo4
may be attractive targets for therapy aimed at control-
ling tumors with enhanced VEGF-C/VEGFR-3 signal-
ing that metastasize through the lymphatic system, and
lymphatic pathology induced by signaling through this
pathway.
Results
Slit2N inhibits VEGF-C-enhanced growth, migration,
and tube formation of L-LECs
To evaluate the effects of Slit/Robo on VEGF-C-modulated
lymphatic endothelial cell functions, we incubated L-LECs
with PBS, Slit2N, VEGF-C, or Slit2N followed by VEGF-C,
and assessed proliferation and migration (Figure 1A and B,
respectively). We observed that Slit2N alone had no sig-
nificant effect on the proliferation of L-LECs; however,
100 ng/ml VEGF-C greatly enhanced their growth, and pre-
treatment with Slit2N significantly inhibited this VEGF-C-
enhanced proliferation (Figure 1A).
In a transwell migration assay, Slit2N had no discern-
ible effect on the migration of L-LECs, however, 100 ng/ml
Yu et al. Cell Communication and Signaling 2014, 12:25 Page 2 of 15
http://www.biosignaling.com/content/12/1/25VEGF-C significantly enhanced migration, and pretreat-
ment with Slit2N inhibited this VEGF-C-enhanced trans-
well migration (Figure 1B).
As an in vitro correlate for lymphangiogenesis [58], we
also assessed the ability of L-LECs to form 2-dimensional,
endothelial cell enclosures on an artificial extracellular
matrix (Figure 1C). While Slit2N alone had no effect
on the average length of L-LEC tubes, average length
increased significantly after 100 ng/ml VEGF-C treat-
ment (Figure 1D). Pretreatment with recombinant
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Figure 1 Slit2N inhibits VEGF-C-enhanced growth, migration and tube formation of L-LECs. (A) Proliferation of L-LECs as assessed by MTS
assay after incubation with control, 10nM Slit2N, or VEGF-C [100 ng/ml]; or after preincubation with Slit2N, then VEGF-C. Data represent the mean ± SD
of 3 independent experiments (*p<0.05). (B) Transwell migration of L-LECs after treatment with control, 10nM Slit2N, or VEGF-C [100 ng/ml]; or after
preincubation with Slit2N, then VEGF-C. Data represent the mean ± SD of 3 independent experiments (***p <0.001). (C) Representative tube formation
assay on ECM of L-LECs after treatment with control, 10nM Slit2N, or VEGF-C [100 ng/ml]; or after preincubation with Slit2N, then VEGF-C. (D) Average
length of L-LEC tubes as assessed by in vitro tube formation assay on ECM after treatment with 10nM Slit2N, VEGF-C [100 ng/ml]; or after preincubation
with Slit2N, then VEGF-C, relative to average tube length of untreated cells (Slit2N “-”, VEGF-C “-”). Data represent the mean ± SD of 3 independent
experiments (*p<0.05). (E) Representative Western blot analysis of Slit2N expression in L-LECs transduced with a control adenovirus (Ctrl) or with an
adenovirus expressing V5-tagged Slit 2 N .G A P D Hu s e da sl o a d i n gc o n t r o l .(F) Average length of L-LEC tubes in L-LECs transduced with a control adenovirus
(Slit2N-Adenovirus “-”) or in L-LECs transduced with a Slit2N-expressing adenovirus (Slit2N-Adenovirus “+”) as assessed by in vitro tube formation assay on
ECM after incubation with control (VEGF-C “-”) or with VEGF-C [100 ng/ml] (VEGF-C “+”), relative to average tube length of untreated L-LECs transduced
with control adenovirus (Slit2N-Adenovirus “-”, VEGF-C “-”). Data represent the mean ± SD of 3 independent experiments (***p<0.001).
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ment (Figure 1D).
To confirm the inhibitory effect of Slit2N on VEGF-C-
induced tube formation, we transduced a Slit2N-expressing
adenovirus or a control virus into L-LECs, and observed
Slit2N expression by Western blot analysis, 24 hours post-
transduction (Figure 1E). Subsequently, we transduced L-
LECs with the Slit2N adenovirus (Slit2N-Adenovirus “+”)
or control (Slit2N-Adenovirus “-”) ,a n de x a m i n e dt u b ef o r -
mation after VEGF-C stimulation (Figure 1F). Both sets of
untreated L-LEC transductants (VEGF-C “-” lanes) formed
relatively short tubes (Figure 1F). While VEGF-C signifi-
cantly enhanced tube length in the control-transduced
L-LECs, VEGF-C did not in the L-LECs transduced with
Slit2N adenovirus (Figure 1F). This is consistent with the
effects of recombinant Slit2N (Figure 1D). Taken to-
gether, these data indicate that Slit2N can inhibit
VEGF-C-enhanced growth, migration and tube forma-
tion in L-LECs, and suggest that Slit2N may inhibit
VEGF-C-induced lymphangiogenesis in vivo.
Studies of VEGF-C in vitro are routinely conducted at
concentrations between 10 ng/ml and 1000 ng/ml [59-62].
We determined that [100 ng/ml] was the lowest concentra-
tion at which VEGF-C had a significant functional effect on
L-LECs (data not shown); therefore, we conducted our
studies at this final concentration.
Slit2N reduces VEGF-C-induced activation of VEGFR-3
To promote lymphangiogenesis, VEGF-C binds to VEGFR-
2 and VEGFR-3, which induces their dimerization, activa-
tion, and the initiation of intracellular signaling [2,63]. We
examined the phosphorylation of VEGFR-2 and VEGFR-3
in L-LECs after incubation with PBS, VEGF-C, or Slit2N
followed by VEGF-C, and observed low, basal phosphoryl-
ation of the VEGFR-3 isoforms in control-treated L-LECs
(Figure 2A and B). Incubation with VEGF-C significantly
enhanced the activation of these isoforms, and Slit2N inhib-
ited this VEGF-C-enhanced activation in a dose-dependent
manner (Figure 2A and B). Similarly, VEGF-C activated
VEGFR-2; however, Slit2N did not significantly inhibit
VEGF-C-induced VEGFR-2 activation (Figure 2C and D).
T h e s ed a t ai n d i c a t et h a tS l i t 2 Np r e d o m i n a n t l ya f f e c t s
L-LEC proliferation, migration, and tube formation by
modulating signaling through VEGF-C and VEGFR-3.
The effects of Slit2N and VEGF-C on total VEGFR-3 levels
and on VEGFR-3 surface presentation/internalization in
L-LECs
The activity of VEGFR-3 is modulated through a variety
of mechanisms, including its association with VEGFR-2
and alpha 5 integrin [64,65]. Using VEGFR-3 immunopre-
cipitation and Western blot analysis, we examined whether
Slit2N disrupted the interaction between VEGFR-3 and ei-
ther of the aforementioned molecules. There was no
discernible basal interaction between VEGFR-3 and alpha 5
integrin, a very low basal interaction between VEGFR-3
and VEGFR-2 in untreated L-LECs, and Slit2N had no ef-
fect on these associations (Additional file 1); therefore, we
examined another potential mechanism by which Slit2N
might inhibit VEGF-C-induced activation of VEGFR-3,
VEGFR-3 internalization [2].
We incubated L-LECs with recombinant Slit2N for 0,
15, and 30 minutes, labeled cell surface proteins with
biotin, lysed the cells to generate total cell lysates, and
isolated the membrane fraction with streptavidin immu-
noprecipitation. By Western blot analysis we examined
the effect of Slit2N on VEGFR-3 levels in the membrane
fraction and total cell lysates. There was no change in
overall VEGFR-3 expression in the total cell lysates
(Figure 3A and C); however, after 15 minutes, Slit2N de-
creased surface VEGFR-3 expression by more than 50%
(Figure 3A and B). After 30 minutes, there was a small
increase in the amount of VEGFR-3 presented on the
cell surface as compared to levels at 15 minutes (Figure 3A
and B). These data indicate that Slit2N induces the internal-
ization of VEGFR-3, but does not affect total VEGFR-3
levels in L-LECs.
To examine the effects of VEGF-C on VEGFR-3, and
the effects of Slit2N on VEGF-C-induced modulation of
VEGFR-3, we incubated L-LECs with VEGF-C for 0,15,
and 30 minutes, or we pretreated L-LECs for 1 hour
with Slit2N, then incubated them with VEGF-C; lysed
the cells, and isolated the membrane fraction from the
total cell lysates as described above. By Western blot
analysis we examined VEGFR-3 levels in the membrane
fraction and total cell lysates. VEGF-C alone decreased
cell surface VEGFR-3 by about 50% after 15 and 30 mi-
nutes incubation. After 15 minutes, total VEGFR-3 levels
were unchanged, but dropped by about 25% after 30 -
minutes (Figure 3D, E, and F). Surface expression of
VEGFR-3 and total VEGFR-3 in L-LECs incubated with
VEGF-C alone for 15 and 30 minutes was nearly identical
to L-LECs pretreated with Slit2N, and then incubated with
VEGF-C for 15 minutes and 30 minutes (Figure 3D, E,
and F). These data indicate that Slit2N has little or no
effect on VEGF-C-induced modulation of VEGFR-3.
Slit2N inhibits VEGF-C-induced PI3K/Akt activity
To determine which VEGF-C/VEGFR-3 signaling path-
ways are affected by Slit2N in L-LECs, we examined the
activation of ERK1/2, a key downstream molecule in the
VEGF-C/VEGFR-3 signaling cascade, and PI3K activity,
which can also be enhanced by signaling through
VEGF-C/VEGFR-3 [59]. We found that neither Slit2N
alone (Additional file 2), nor Slit2N pretreatment be-
fore VEGF-C incubation, affected the phosphorylation
of ERK1/2 in L-LECs (Figure 4A and B); however, PI3K
activity increased significantly after treatment with
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Slit2N completely inhibited this VEGF-C-enhanced ac-
tivity (Figure 4C). We also examined the effects of
VEGF-C and Slit2N on the activation of the PI3K
downstream signaling molecule, Akt. We found that
Slit2N alone had no effect on Akt activation (Additional
file 3); however, VEGF-C significantly enhanced Akt
phosphorylation in L-LECs, and pretreatment with Slit2N
decreased its activation in a dose-dependent manner
(Figure 4D and E). These data indicate that Slit2N
inhibits VEGF-C-induced activation of PI3K/Akt, but
not VEGF-C-induced activation of ERK1/2. The differ-
ences in the effects of Slit2N on these VEGF-C/VEGFR-3
effectors suggest that there are likely other signaling mole-
cules in these pathways that are differentially modulated
by Slit2N.
Robo4 is required for Slit2N to inhibit the activation of
VEGFR-3 by VEGF-C
Among the Slit receptors, Robo4 is expressed almost exclu-
sively in proliferating endothelium and tumor endothelium
[45,66]; however, a recent study has also demonstrated
Robo1 expression in human lymphatic endothelial cells and
its interaction with Slit2 [56]; therefore, by Western
blot analysis, we compared the levels of Robo4 and
Robo1 in primary L-LECs, primary dermal HMVECs,
and 293/VEGFR-3, human embryonic kidney cells ma-
nipulated to express VEGFR-3 (as a non-endothelial
control). All three cell types expressed Robo1: highest
in the HMVECs and lowest in the L-LECs (Figure 5A).
Both types of primary endothelial cells expressed Robo4;
however, its expression was much higher in L-LECs as
compared to HMVECs (Figure 5A). Consistent with its
nearly exclusive endothelial expression, we detected no
Robo4 in the 293/VEGFR-3 cells (Figure 5A). Since L-LECs
expressed the highest comparative levels of Robo4 and the
lowest comparative levels of Robo1, we focused on the po-
tential effects of Robo4 on Slit2N-mediated inhibition of
VEGF-C/VEGFR-3 signaling in these cells.
We transiently transfected a red fluorescent protein
(RFP)-tagged Robo4 expression plasmid or a vector con-
trol into the 293/VEGFR-3 cells. By Western blot ana-
lysis, we confirmed that while Robo4 was not expressed
in the control-transfected cells, it was expressed in the
cells transfected with the Robo4 plasmid; and Robo1
expression was identical in both sets of transfectants
(Figure 5B). We incubated these cells with PBS, Slit2N,
VEGF-C, or Slit2N followed by VEGF-C, immunopreci-
pitated with VEGFR-3, and examined the phosphoryl-
ation of the VEGFR-3 isotypes by Western blot analysis,
using a phospho-tyrosine antibody (Figure 5C). Acti-
vated VEGFR-3 was not expressed in the untreated 293/
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Figure 2 Slit2N attenuates VEGF-C-induced activation of VEGFR-3 in L-LECs. (A) Representative VEGFR-3 IP/Western blot analysis of phosphorylated
VEGFR-3 in L-LECs after pretreatment with various concentrations of Slit2N, and incubation with VEGF-C [100 ng/ml]. Total VEGFR-3 used as loading control.
(B) Quantitative analysis of VEGFR-3 IP/Western blot analysis of phosphorylated VEGFR-3 in L-LECs after pretreatment with various concentrations of Slit2N,
and incubation with VEGF-C. Band intensities from Figure 2A were determined by densitometry. The ratio of p-VEGFR-3/total VEGFR-3 of L-LECs treated
with VEGF-C alone (2
nd lanes from the left) was set to “1” and the ratios of all other conditions were calculated vs. this experimental condition. Data
represent the mean ± SD of 3 independent experiments (*p<0.05; **p<0.01). (C) Representative Western blot analysis of phosphorylated VEGFR-2 in
L-LECs after pretreatment with various concentrations of Slit2N, and incubation with VEGF-C [100 ng/ml]. Total VEGFR-2 used as loading control.
(D) Quantitative analysis of Western blot analysis of phosphorylated VEGFR-2 in L-LECs after pretreatment with various concentrations of Slit2N, and
incubation with VEGF-C. Band intensities from Figure 2C were determined by densitometry. The ratio of p-VEGFR-2/total VEGFR-2 of L-LECs treated
with VEGF-C alone (2
nd lanes from the left) was set to “1” and the ratios of all other conditions were calculated vs. this experimental condition. Data
represent the mean ± SD of 3 independent experiments.
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plasmid or the Robo4-RFP plasmid, and incubation with
Slit2N alone had no effect on VEGFR-3 phosphorylation in
either group of transfectants (Figure 5C and D, Vector +/−
and Robo4 +/−). VEGF-C induced VEGFR-3 activation in
both groups of transfectants (Figure 5C and D, Vector −/+
and Robo4 −/+). Treatment with Slit2N before VEGF-C
incubation had no effect on activation of the VEGFR-3
isoforms in the vector control group (Figure 5C and D,
Vector +/+); however, Slit2N inhibited VEGFR-3 activation
in the Robo4-expressing transfectants (Figure 5C and D,
Robo4 +/+). These data indicate that Robo4 expression is
not required for VEGF-C-induced activation of VEGFR-3
in 293/VEGFR-3 cells; however, sufficient levels of Robo4
are required for Slit2N-modulated inhibition of VEGF-C-
induced VEGFR-3 activation.
To extend this finding to lymphatic endothelial cells,
we transiently transfected L-LECs with control siRNAs
or Robo4-specific siRNAs. After 24 hours, we confirmed
a reduction in Robo4 expression by Western blot
analysis, and a low, unchanged Robo1 expression in
both sets of transfectants (Figure 5E). We incubated
these transfectants with PBS, Slit2N, VEGF-C, or Slit2N
followed by VEGF-C, immunoprecipitated with VEGFR-
3, and examined VEGFR-3 phosphorylation by immuno-
blot, as above. We observed no VEGFR-3 activation in
either group of untreated L-LEC transfectants (Figure 5F
and G, Control siRNA −/− and Robo4 siRNA −/−)a n d
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Figure 3 Effects of Slit2N and VEGF-C on total VEGFR-3 levels and VEGFR-3 surface presentation/internalization in L-LECs. (A) Representative
Western blot analysis of surface and total VEGFR-3 in L-LECs after incubation with 10nM Slit2N for indicated times. GAPDH: loading control. (B) Quantitative
analysis of surface VEGFR-3 in L-LECs after incubation with 10nM Slit2N for indicated times. Band intensities from Figure 3A were determined
by densitometry. Ratio of surface VEGFR-3/GAPDH in untreated L-LECs (“0” lanes) was set to “1” and values of other ratios were calculated vs. this
control. (C) Quantitative analysis of total VEGFR-3 in L-LECs after incubation with 10nM Slit2N for indicated times. Band intensities from Figure 3A were
determined by densitometry. Ratio of total VEGFR-3/GAPDH in untreated L-LECs (“0” lanes) was set to “1” and values of other ratios were calculated vs.
untreated control. (D) Representative Western blot analysis of membrane-bound VEGFR-3 (Surface VEGFR-3) and total VEGFR-3 in L-LECs after incubation
with VEGF-C alone [100 ng/ml], and 10nM Slit2N pretreatment+VEGF-C for indicated times. GAPDH: loading control. (E) Quantitative analysis of surface
VEGFR-3 in L-LECs after incubation with VEGF-C alone [100 ng/ml] (Control), and 10nM Slit2N pretreatment+VEGF-C for indicated times. Band intensities
from Figure 3D were determined by densitometry. Ratio of surface VEGFR-3/GAPDH of untreated L-LECs was set to “1” and values of all other
ratios were calculated vs. untreated control. (F) Quantitative analysis of total VEGFR-3 in L-LECs after incubation with VEGF-C alone [100 ng/ml]
(Control), and 10nM Slit2N pretreatment+VEGF-C for indicated times. Band intensities from Figure 3D were determined by densitometry. Ratio of total
VEGFR-3/GAPDH of untreated L-LECs was set to “1” and values of other ratios were calculated vs. untreated control. Data for (B), (C), (E) and (F) represent
the mean ± SD of 3 independent experiments (***p <0.001).
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http://www.biosignaling.com/content/12/1/25VEGF-C induced the phosphorylation of VEGFR-3 in
both groups of transfectants (Figure 5F and G, Control
siRNA −/+ and Robo4 siRNA −/+). Pretreatment with
Slit2N inhibited the VEGF-C-induced activation of VEGFR-3
in the L-LECs with endogenous Robo4 expression (Figure 5F
and G, Control siRNA +/+); however, it had no discernible
effect on VEGFR-3 activation in the L-LECs with reduced
levels of Robo4 (Figure 5F and G, Robo4 siRNA +/+).
These data indicate that Robo4 is not required for VEGF-
C-induced activation of VEGFR-3 in L-LECs; however,
adequate expression of Robo4 is required for Slit2N to in-
hibit this activation. These data suggest a role for Robo4
in the Slit2N-modulated inhibition of VEGF-C-mediated
effects in lymphatic endothelium.
Robo4 is required for Slit2N to inhibit VEGF-C-induced
PI3K/Akt activity in L-LECs
To determine if Slit2N inhibition of VEGF-C-induced
PI3K/Akt activation is Robo4-dependent, we used L-LECs
transfected with control siRNAs or Robo4-specific siRNAs,
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Figure 4 Slit2N inhibits VEGF-C-enhanced PI3K activity and Akt phosphorylation in L-LECs. (A) Representative Western blot analysis of
phosphorylated ERK1/2 in L-LECs, after treatment with control, VEGF-C alone [100 ng/ml]; or after preincubation with various concentrations of
Slit2N, then VEGF-C. Total ERK1/2 used as loading control. (B) Quantitative analysis of phosphorylated ERK1/2 in L-LECs, after treatment with
control, VEGF-C alone [100 ng/ml]; or after preincubation with various concentrations of Slit2N, then VEGF-C. Band intensity of each lane from
Figure 4A was determined by densitometry. The ratio of p-ERK1/2 to total ERK1/2 of L-LECs incubated with VEGF-C alone was set to “1” and
values of all other ratios were calculated vs. this control. Data represent the mean ± SD of 3 independent experiments. (C) PI3K activity by
ELISA in L-LECs incubated with various concentrations of Slit2N and/or VEGF-C [100 ng/ml]. Data represent the mean ± SD of 3 independent
experiments (**p<0.01, ***p<0.001). (D) Representative Western blot analysis of phosphorylated Akt in L-LECs incubated with a control, VEGF-C [100 ng/ml];
or preincubated with various concentrations of Slit2N, then VEGF-C. Total Akt used as loading control. (E) Quantitative analysis of phosphorylated Akt
in L-LECs, after treatment with control, VEGF-C alone [100 ng/ml]; or after preincubation with various concentrations of Slit2N, then VEGF-C. Band intensity
of each lane from Figure 4D was determined by densitometry. The ratio of p-Akt to total Akt of L-LECs incubated with VEGF-C alone was set to “1” and
values of all other ratios were calculated vs. this control. Data represent the mean ± SD of 3 independent experiments (**p <0.01).
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treated control siRNA-transfected cells to “1” and calcu-
lated the fold change in activity after incubation with
VEGF-C, or after incubation with Slit2N followed by
VEGF-C, relative to the untreated controls (Figure 6A). In-
cubation with VEGF-C enhanced PI3K activity in both sets
of transfectants by nearly 100% (Figure 6A). Pretreatment
with Slit2N significantly decreased VEGF-C-enhanced PI3K
activity in the control siRNA-transfected L-LECs; however,
Slit2N had no discernible effect on the cells with reduced
Robo4 expression (Figure 6A). These data indicate that
Robo4 is required to affect Slit2N-mediated inhibition of
VEGF-C-enhanced PI3K activity in L-LECs.
We also examined the role of Robo4 on the Slit2N in-
hibition of VEGF-C-induced activation of Akt, using the
same L-LEC transfectants and conditions described
above. We found no Akt activation in either group of
untreated transfectants; likewise, Slit2N alone did not
Figure 5 Slit2N inhibits VEGF-C-induced activation of VEGFR-3 in 293/VEGFR-3 transfectants and L-LECs in a Robo4-dependent manner.
(A) Representative Western blot analysis of Robo1 and Robo4 expression in L-LECs, HMVECs, and 293/VEGFR-3 cells. GAPDH used as loading control.
(B) Representative Western blot analysis of Robo4 and Robo1 expression in 293/VEGFR-3 cells, 24 h after transfection with pCMV-RFP (vector) or
pCMV-RFP-Robo4 (Robo4). GAPDH used as loading control. (C) Representative VEGFR-3 IP/Western blot analysis of phosphorylated VEGFR-3.
293/VEGFR-3 cells were transfected with pCMV-RFP (vector) or pCMV-RFP-Robo4 (Robo4). After 48 h, cells were incubated with a control
(“-- ”), 10nM Slit2N, or VEGF-C [100 ng/ml]; or pretreated with Slit2N, then VEGF-C. Total VEGFR-3 used as loading control. (D) Quantitative
analysis by densitometry of Figure 5C. The ratio of p-VEGFR-3/VEGFR-3 in vector-transfected L-LECs incubated with VEGF-C alone was set to
“1” and all other ratios were determined vs. this control. Data represent the mean ± SD of 3 independent experiments (***p<0.001).
(E) Representative Western blot analysis of Robo4 and Robo1 expression in L-LECs, 24 h after transfection with control siRNAs or Robo4-specific
siRNAs. GAPDH used as loading control. (F) Representative VEGFR-3 IP/Western blot analysis of phosphorylated VEGFR-3 in L-LECs transfected with control
siRNAs or Robo4-specific siRNAs, after incubation with control, VEGF-C [100 ng/ml]; or pretreatment with 10nM Slit2N, then VEGF-C. Total VEGFR-3 used as
loading control. (G) Quantitative analysis by densitometry of Figure 5F. The ratio of p-VEGFR-3/VEGFR-3 in control siRNA-transfected L-LECs incubated with
VEGF-C alone was set to “1” and all other ratios were determined vs. this control. Data represent the mean ± SD of 3 independent experiments (*p<0.05).
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http://www.biosignaling.com/content/12/1/25induce Akt activation (Figure 6B and C). Incubation with
VEGF-C induced similar levels of Akt phosphorylation
in both sets of transfectants; however, pretreatment
with Slit2N significantly reduced VEGF-C-induced Akt
activation only in the transfectants with endogenous
Robo4 levels (Figure 6B and C, Control siRNA +/+).
Slit2N had no effect on the VEGF-C-induced activation
of Akt in the L-LECs with reduced Robo4 levels
(Figure 6B and C, Robo4 siRNA +/+). These data indi-
cate that Slit2N can inhibit VEGF-C-induced activation
of Akt in L-LECs, and that inhibition by Slit2N is
Robo4-dependent.
Slit2N inhibition of VEGF-C-enhanced growth, migration,
and tube formation of L-LECs is Robo4-dependent
Finally, we queried if Robo4 was required for Slit2N to in-
hibit the proliferation, migration, and tube formation of
L-LECs enhanced by VEGF-C. We repeated the functional
assays, illustrated in Figure 1A, B, and D, in L-LEC transi-
ent transfectants, which expressed control siRNAs or
Robo4-specific siRNAs, as previously described. In these
assays, we set the average proliferation levels, migration
levels, and tube lengths of untreated control siRNA trans-
fectants to “1,” and calculated the fold change after incu-
bation with recombinant Slit2N and/or VEGF-C, relative
to the untreated controls (Figure 7). Slit2N alone had no
effect on any of these functions in either set of transfec-
tants, but incubation with VEGF-C enhanced proliferation,
transwell migration and average tube length significantly
(Figure 7A, B, and C, respectively). Moreover, VEGF-C en-
hanced these activities to a similar extent in both groups of
L-LEC transfectants (Figure 7). When we pretreated the cells
with Slit2N before incubating them with VEGF-C, there
was a significant inhibition of VEGF-C-enhanced prolifera-
tion, migration, and tube length of the L-LEC transfectants
with endogenous Robo4 expression (Control siRNA, +/+,
Figure 7A, B, and C, respectively); however, Slit2N had no
significant effect on these VEGF-C-enhanced activities in
the L-LEC transfectants with diminished Robo4 levels
(Robo4 siRNA, +/+, Figure 7A, B, and C). These data indi-
cate that sufficient levels of Robo4 appear to be necessary
for Slit2N to inhibit these VEGF-C-enhanced functions.
Discussion
While earlier studies revealed a role for Slit2 and Robo4
in modulating vascular endothelial functions [52-54],
there is limited information on the effects of this ligand
and receptor in lymphatic endothelium. We found that
VEGF-C enhanced the proliferation, migration, and tube
formation of L-LECs (Figure 1). These in vitro functions
have in vivo correlates that are critical components of
lymphangiogenesis [67]. Slit2N inhibited these enhanced
functions (Figure 1) by modulating signaling through
VEGF-C and its cognate receptor, VEGFR-3 (Figure 2).
Our results provide a mechanism to elucidate previous
results, e.g., that Slit2 treatment of cells of endothelial
and epithelial origin inhibited their migration and
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Figure 6 Slit2N inhibition of VEGF-C-enhanced PI3K activity and
Akt phosphorylation in L-LECs is Robo4-dependent. (A) PI3K
activity by ELISA in L-LECs transfected with control siRNAs or Robo4-
specific siRNAs, incubated with control or VEGF-C [100 ng/ml]; or
after pretreatment with 10nM Slit2N, then VEGF-C. Data represent
the mean ± SD of 3 independent experiments (*p< 0.05; NS: not
statistically significant). (B) Representative Western blot analysis of
Akt phosphorylation in L-LECs transiently transfected with control
siRNAs or Robo4-specific siRNAs, and subsequently incubated with
10 nM Slit2N, VEGF-C [100 ng/ml]; or after pretreatment with Slit2N,
then VEGF-C. Total Akt used as loading control. (C) Quantitative
analysis of Akt phosphorylation in L-LECs transiently transfected with
control siRNAs or Robo4-specific siRNAs, and subsequently incubated
with 10nM Slit2N, VEGF-C [100 ng/ml]; or after pretreatment with
Slit2N, then VEGF-C. Band intensity of each lane from Figure 6B was
determined by densitometry. The ratio of p-Akt/total Akt in control
siRNA-transfected L-LECs incubated with VEGF-C alone was set to “1”
and all other ratios were determined vs. this control. Data represent
the mean ± SD of 3 independent experiments (***p<0.001).
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tastasis in vivo [72,73].
In contrast, a prior study by Yang et al. concluded that
Slit2 enhanced the in vitro tube formation of dermal
HMVECs [56]; however, skin-derived endothelial cells
and lung-derived endothelial cells have different Robo
expression profiles (Figure 5A). HMVECs express high
levels of Robo1 and low Robo4. The L-LECs used in our
study express high levels of Robo4 (Figure 5A). This sug-
gests that pro- or anti-lymphangiogenic effects of Slit2
may be modulated by multiple factors including the tis-
sue of origin and the Robo receptor with which Slit2
interacts.
Receptor tyrosine kinases (RTKs), including the VEGF
receptors, typically are activated by their cognate ligands
and modulated by a variety of biological processes in-
cluding dimerization, internalization, degradation, and
receptor presentation [2,61,67,74,75]. Internalization and
activation of both VEGFR-2 and VEGFR-3 can trigger
downstream signaling through the MAP kinases ERK1/2
and PI3K/Akt in vascular endothelial cells [59,76]. We
provide new evidence that pretreatment with Slit2N can
inhibit VEGF-C-induced PI3K/Akt signaling in L-LECs
(Figure 4C, D, and E), thereby modulating VEGFR-3
presentation levels on the cell surface (Figure 3D and E).
Although both Slit2N and VEGF-C alone induced the in-
ternalization of VEGFR-3 (Figure 3A, B, D, and E), only
VEGF-C decreased total VEGFR-3 levels, and Slit2N pre-
treatment did not alter these VEGF-C-induced effects on
VEGFR-3 (Figure 3F). These data suggest that Slit2N and
VEGF-C may decrease VEGFR-3 surface expression by
different mechanisms. One potential explanation is that
Slit2N alone may induce the endocytosis of VEGFR-3 into
clathrin-mediated endosomes, which traffic back to the cell
membrane and facilitate the recycling of VEGFR-3 on the
cell surface [2]. The increase in surface VEGFR-3 between
15 and 30 minutes post-incubation with Slit2N is consistent
with this hypothesis (Figure 3A and B). After incubat-
ing with VEGF-C for 15 minutes, surface expression of
VEGFR-3 decreased by half and remained at that level
30 minutes post-incubation; however, after 30 minutes,
total VEGFR-3 levels also decreased (Figure 3D, E, and
F). These data suggest that VEGF-C does not induce
the recycling of VEGFR-3 to the cell surface; rather,
they suggest that VEGF-C may target VEGFR-3 to the
lysosomes for degradation.
Our work and that of others have shown that Slit2 af-
fects cytoskeletal reorganization, largely by regulating
actin polymerization, and by modulating cytoskeletal sig-
naling pathways and the association of key cytoskeletal
proteins, including actin [77], WASp [77,78], LSP1 [77],
Arp2/3 [77,78], mDia2 (our unpublished data), Fli1 (our
unpublished data), paxillin [52,79] and Arf6 [52,79]. Of
note, the latter two proteins are important molecules for
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Figure 7 Slit2N inhibits VEGF-C-enhanced growth, migration,
and tube formation of L-LECs in a Robo4-dependent manner.
(A) Proliferation of L-LECs transiently transfected with control
siRNAs or Robo4-specific siRNAs as assessed by MTS assay after
treatment with control, 10 nM Slit2N, VEGF-C [100 ng/ml]; or after
preincubation with Slit2N, then VEGF-C. Data represent the mean ± SD
of 3 independent experiments (**p<0.01; NS: not statistically significant).
(B) Transwell migration of L-LECs transiently transfected with control
siRNAs or Robo4-specific siRNAs after treatment with control, 10 nM
Slit2N, VEGF-C [100 ng/ml]; or after preincubation with Slit2N,
then VEGF-C. Data represent the mean ± SD of 3 independent
experiments (***p<0.001; NS: not statistically significant).
(C) Relative length of tubes formed by L-LECs transiently transfected
with control siRNAs or Robo4-specific siRNAs as assessed by in vitro
tube formation assay on ECM after treatment with control, 10 nM
Slit2N, VEGF-C [100 ng/ml]; or after preincubation with Slit2N,
then VEGF-C. Data represent the mean ± SD of 3 independent
experiments (*p<0.05; NS: not statistically significant). For panels A, B,
and C, proliferative index, migration index, and relative tube length,
respectively, were set to “1” for control-siRNA-transfected,
untreated cells. Data for all other conditions were calculated
relative to these controls.
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tor internalization and cell surface presentation [52,80].
By modulating the cytoskeleton, Slit2 has been shown to
enhance vascular stability [52,79], inhibit HIV-induced
migration of dendritic cells [77], inhibit the infection of
CD4
+ T-cells by HIV-1 [81], block cell-to-cell transmission
of HIV-1 (our unpublished data), and inhibit PDGF-
induced migration of smooth muscle cells [78]. Therefore,
we hypothesize that Slit2N induces the internalization
of VEGFR-3 by modulating the L-LEC cytoskeleton.
Additional experiments are needed to elucidate the
specific cytoskeletal proteins affected by Slit2N that in-
duce VEGFR-3 internalization in these cells.
L-LECs secrete Slit2 and express Robo1 and Robo4
([82] and Figure 5A). Currently, there are two hypoth-
eses by which Slit2 may signal through Robo4. One
suggests that Slit2 binds directly to Robo4 to initiate
downstream signaling [48,66]. The other proposes that
Slit2 binds to Robo1, which then transactivates Robo4 to
initiate signaling [83]. We demonstrated that Slit2N inhib-
ited VEGF-C signaling in cells manipulated to express
Robo4, but not in corresponding controls that did not ex-
press Robo 4 (Figure 5C and D). Similarly, Slit2N inhibited
VEGF-C-induced signaling in L-LECs which expressed
moderate levels of Robo4, but not in L-LECs which ex-
pressed significantly reduced levels of Robo4 (Figure 5E, F,
and G). Taken together, these data, and the robust expres-
sion of Robo4 on endothelial cells, suggest that the inhibitory
effect of Slit2N on VEGF-C-induced signaling in L-LECs
is predominantly through Robo4; however, L-LECs also
express Robo1, albeit at much lower levels (Figure 5A).
To assess the potential contribution of Robo1 to the in-
hibitory effects of Slit2N/Robo4 in our study, we trans-
fected L-LECs with control siRNAs or with Robo1-specific
siRNAs, and repeated the functional assays illustrated in
Figure 7. Incubation with VEGF-C enhanced proliferation,
transwell migration and average tube length significantly,
and Slit2N inhibited these VEGF-C enhanced activities in
both sets of L-LEC transfectants (Additional file 4A, B, and
C). These data indicate that Robo1 is not required for in-
hibition by Slit2N, and it does not contribute to Slit2N/
Robo4 signaling in the lung lymphatic endothelial cells used
in this study.
Conclusions
Our data demonstrate a novel role for Slit2N and Robo4 in
the inhibition of functions critical for lymphangiogenesis
and lymphatic tumor metastasis, including L-LEC prolifera-
tion, migration, and tube formation. This study supports
continued characterization of these novel, lymphatic modu-
lators and their potential therapeutic applications for the
treatment of pathologies associated with lymphatic endo-
thelial dysfunction.
Methods
Cells
Primary human L-LECs and primary dermal HMVECs
were purchased from Lonza, Inc. (Allendale, NJ), cultured
in EBM-2 plus EGM-2MV SingleQuots (Lonza, Inc.) at
37°C and 5% CO2, and used between passages 4 and 6
for experiments described herein. 293/VEGFR-3 cells
(Genentech, Inc., San Francisco, CA) were cultured in
DMEM, 10% FBS at 37°C and 5% CO2.
Reagents
VEGF-C and Slit2N were purchased from ProSpec (East
Brunswick, NJ) and PreproTech, Inc. (Rocky Hill, NJ),
respectively. Antibodies used include anti-VEGFR-3,
anti-p-Tyr, anti-GAPDH, and anti-p-ERK1/2 (Santa Cruz
Biotechnology, Santa Cruz, CA); anti-p-Akt (Ser-473), anti-
VEGFR-2 (55B11), anti-p-VEGFR-2 (Tyr1175), anti-ERK1/
2 (9102), and anti-Akt (4685) (Cell Signaling Technology,
Beverly, MA); anti-PI3K p85 (Upstate Biotechnology,
Waltham, MA), anti-Robo1 (ab7279), and anti-Robo4
(ab10547) (Abcam Inc., Cambridge, MA).
Robo4 expression plasmid transfections and Robo4
expression evaluation
pCMV6-AC-RFP and pCMV6-AC-RFP-Robo4 plasmids
[82], were transfected into 293/VEGFR-3 cells using Super-
Fect® Transfection Reagent per manufacturer’si n s t r u c t i o n s
(Qiagen Inc. - USA, Valencia, CA). Robo4 protein levels
were determined by Western blot analysis 24 hours after
transfection, as previously described [82].
Construction of the Slit2N adenoviral expression plasmid,
viral packaging, transduction, and Slit2N expression
evaluation
The ViraPower™ Adenoviral Expression System (Life
Technologies, Woburn, MA), which included 293A
packaging cells, was used to express Slit2N per manu-
facturer’s instructions.
To construct the Slit2N ENTRY clone, the Slit2N gene
was amplified from pCMV-ENTRY-Slit2N (OriGene
Technologies, Inc., Rockville, MD) using the following
primers: 5′- CAC CAT GCG CGG CGT TGG CTG
GCA GAT GC and 5′- GGG ACC ATG GGT GGA
GAA AAC TC. The PCR product was then cloned into
the pENTR™/D-TOPO® vector.
The Slit2N expression clone in which Slit2N is fused
to a C-terminal V5 tag was generated by performing the
LR reaction between pENTR/D-TOPO-Slit2N and pAD/
CMV/V5-DEST (Life Technologies) per manufacturer’s
instructions. The expression construct was cut with PAC1
and transfected into 293A cells to produce the adenoviral
stock. The adenovirus was transduced into L-LECs, and ex-
pression levels of Slit2N confirmed after 24 to 48 hours by
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V5 antibody (Life Technologies).
siRNA transfections and Robo expression evaluation
Robo1- and Robo4-specific and control siRNAs (Santa
Cruz Biotechnology, Inc.) were transfected into cells using
HiPerFect® Transfection Reagent per manufacturer’si n -
structions (Qiagen, Inc). Robo protein expression in each
group of transfectants was determined by Western blot
analysis, 24 hours post-transfection. Cell proliferation
assay – CellTiter 96® AQueous One Solution Cell Prolifera-
tion Assay (MTS) was purchased from Promega Corp.
(Madison, WI). Twenty-four hours after receiving fresh
media, L-LECs (80% confluent) were trypsinized and
washed twice with PBS. Cell suspensions of 2 × 10
5 cells/
ml were incubated with a control or 10 nM Slit2N in star-
vation media (0.5% BSA/DMEM) for 1 hour. Subsequently,
50 μl of each was seeded into 96-well plates, and 50 μlo f
starvation medium with/without VEGF-C [100 ng/ml] was
added to the wells before incubating the cells at 37°C. After
24 hours, 20 μl of CellTiter 96® AQueous One Solution Cell
Proliferation reagent was added to each well, and incubated
at 37°C for 2 hours. Data were collected at OD490.
Cell migration assay
L-LEC migration assay was performed using 24-well
transwell permeable supports with 6.5 μm pore filters
(Corning, Inc., Lowell, MA). The undersides of the filters
were coated with 25 ng/ml fibronectin. Twenty-four
hours after receiving fresh media, L-LECs were trypsi-
nized, rinsed twice with PBS, resuspended to 1 × 10
5
cells/ml, and pretreated with 10 nM Slit2N. After 1 hour,
100 μl of the cell suspension was added to the top cham-
ber of each transwell. Starvation media (0.5% BSA/
DMEM) (600 μl) with/without VEGF-C [100 ng/ml] was
added to each lower chamber. The cells were incubated
at 37°C, 5% CO2, for 4 hours. Non-migrated cells were
removed from the upper chambers by swiping the upper
surface with a cotton swab. Migrated cells on the under-
side were fixed and stained with Diff-Quik® stain kit
(Siemens Healthcare Diagnostics, Inc., Newark, DE).
Eight high-power fields per filter were counted. Migration
index was calculated as the average number of migrated
cells incubated with Slit2N, VEGF-C, or both vs. the aver-
age number of migrated cells incubated with neither Slit2N
nor VEGF-C.
Tube formation assay
L-LEC tube formation was assessed with the In Vitro
Angiogenesis Assay Kit (ECM625) (Millipore, Corp.,
Bedford, MA) per manufacturer’s instructions. Briefly,
plates were coated with ECMatrix™, artificial extracellu-
lar matrix (ECM), and incubated for at least 1 hour at
37°C, 5% CO2. Twenty-four hours after receiving fresh
media, L-LECs were trypsinized and washed twice with
PBS. Cell suspensions of 2 × 10
5 cells/ml were preincu-
bated with PBS or 10 nM Slit2N in 0.5% BSA/DMEM
for 1 hour. Subsequently, 50 μl of each was seeded onto
the ECM-coated plates, then 50 μl 0.5% BSA/DMEM
with/without VEGF-C [100 ng/ml] was added to the
wells before incubating the cells at 37°C overnight. Ca-
pillary tube formation images were captured with a
digital microscope camera system (100×) in 5 randomly
selected fields in each of the wells. “UTHSCSA Image-
Tool” software (Dept. of Dental Diagnostic Science, Uni-
versity of Texas Health Science Center, San Antonio,
TX) was used to quantify the length of tubes per field.
Data represent the average tube length ± SD, 3 wells per
condition, 5 fields per well. To analyze the effect of
Slit2N transduction on VEGF-C-induced tube formation,
L-LECs were transduced with control or Slit2N adeno-
virus. Twenty-four hours after transduction, the cells
were seeded onto the ECM-coated plates with/without
VEGF-C [100 ng/ml], and incubated at 37°C overnight.
Slit2N and VEGF-C final concentrations and incubation
times
For all signaling and receptor internalization studies,
Slit2N was used at [10 nM] and VEGF-C was used at
[100 ng/ml], unless otherwise stated. In these studies,
L-LECs were incubated with Slit2N for 1 hour and with
VEGF-C for 15 minutes, unless otherwise stated.
PI3K activity
PI3K activity was assayed with the PI3-Kinase Activity
ELISA: Pico (Echelon Biosciences, Inc., Salt Lake City, UT).
Twenty-four hours after receiving fresh media, L-LECs
were incubated in 0.5% BSA/DMEM and 0-10 nM Slit2N
for 1 hour, then incubated with/without VEGF-C [100 ng/
ml] for 15 minutes. The cells were rinsed, lysed and centri-
fuged per manufacturer’s instructions. The supernatants
were collected and incubated with an anti-PI3K p85 anti-
body for 1 hour at 4°C. A 50% slurry of Protein A-agarose
beads/PBS (60 μl) was added to each tube, and gently
rocked for 1 hour at 4°C. The beads were centrifuged and
washed to isolate PI3K. PI3K activity was assayed with a
kinetic microplate reader (Molecular Devices, Sunnyvale,
CA), and absorbance read at 450 nm.
Immunoprecipitation and Western blot analysis
L-LECs or 293/VEGFR-3 were incubated with PBS or
various concentrations of Slit2N for 1 hour, and then
stimulated with VEGF-C [100 ng/ml] or PBS as indi-
cated. Cells were washed with PBS and lysed with RIPA
buffer plus a protease inhibitor cocktail (cat. #5871, Cell
Signaling). Lysates were incubated on ice for 30 minutes
before being centrifuged at 13,000 g for 30 minutes.
Immunoprecipitation and Western blot analysis were
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protein from Western blot analyses, blots were scanned,
and band intensity measured using ImageJ software
(NIH, Bethesda, MD). For each blot analyzed, one condi-
tion was identified as the control as stated in figure leg-
ends, and its value established as “1.” All other values
were calculated relative to this control.
VEGFR-3 internalization assay
Cell surface biotinylation was performed in a 100 mm
dish. Twenty four hours after receiving fresh media, L-
LECs were incubated in 0.5% BSA/DMEM and 10 nM
Slit2N alone for 15 and 30 minutes, with VEGF-C alone
[100 ng/ml] for 15 and 30 minutes, or incubated with 10
nM Slit2N for 1 hour before incubation with VEGF-C
[100 ng/ml] for 15 and 30 minutes. Subsequently, sur-
face receptors were labeled with Sulfo-NHS-LC-Biotin
(Thermo Fisher Scientific, Waltham, MA) per manufac-
turer’s instructions. After quenching excess biotin with
100 mM quenching buffer, the cells were washed with
TBS, and dissolved in 0.8 ml RIPA buffer to create whole
cell lysates. To measure cell surface VEGFR-3, a fraction
of the lysates was precipitated with streptavidin agarose
beads (Life Technologies). The beads were washed, and
proteins were extracted by boiling with sample buffer
before Western blot analysis. The total VEGFR-3 expres-
sion was analyzed using the remaining whole cell lysates.
Statistical analysis
Statistical analyses were performed using a standard
two-tailed Student’s T-test. p-values less than 0.05 were
considered statistically significant.
Additional files
Additional file 1: Slit2N has no effect on the association of VEGFR-3
with VEGFR-2 or with Alpha 5 integrin. VEGFR-3 immunoprecipitation
and Western blot analysis of VEGFR-2 and Alpha 5 integrin, with and
without Slit2N incubation, in L-LECs. VEGFR-3 used as loading control.
Additional file 2: Slit2N has no effect on the activation of ERK1/2 in
L-LECs. Western blot analysis of phosphorylated ERK1/2 in L-LECs incubated
for various times with Slit2N [10 nM]. Total ERK1/2 used as loading control.
Additional file 3: Slit2N has no effect on the activation of Akt in
L-LECs. Western blot analysis of phosphorylated Akt in L-LECs incubated for
various times with Slit2N [10 nM]. Total Akt used as loading control.
Additional file 4: Robo1 is not required for Slit2N to inhibit VEGF-
C-enhanced growth, migration, and tube formation of L-LECs. (A)
Proliferation of L-LECs transiently transfected with control siRNAs or
Robo1-specific siRNAs as assessed by MTS assay after treatment with
control, 10 nM Slit2N, VEGF-C [100 ng/ml]; or after preincubation with
Slit2N, then VEGF-C. Data represent the mean ± SD of 3 independent
experiments (**p < 0.01; ***p < 0.001). (B) Transwell migration of L-LECs
transiently transfected with control siRNAs or Robo1-specific siRNAs
after treatment with control, 10 nM Slit2N, VEGF-C [100 ng/ml]; or after
preincubation with Slit2N, then VEGF-C. Data represent the mean ± SD
of 3 independent experiments (**p <0.01; ***p<0.001). (C) Relative
length of tubes formed by L-LECs transiently transfected with control
siRNAs or Robo1-specific siRNAs as assessed by in vitro tube formation
assay on ECM after treatment with control, 10 nM Slit2N, VEGF-C
[100 ng/ml]; or after preincubation with Slit2N, then VEGF-C. Data
represent the mean ± SD of 3 independent experiments (***p< 0.001).
For panels A, B, and C, proliferative index, migration index, and relative
tube length, respectively, were set to “1” for control-siRNA-transfected,
untreated cells. Data for all other conditions were calculated relative
to these controls.
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